Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Glycotope","sponsor":"Byondis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Byondis , Glycotope Enter Platform Access Agreement Discovery and Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Glycotope","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Glycotope","sponsor":"Therabest","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Therabest and Glycotope to Assess Therabest\u2019s iPSC-derived NK Cell Product TB-100 in Combination with Glycotope\u2019s GT-00AxIL15 Immuno-cytokine For Development In Triple Negative Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Glycotope","sponsor":"Max Delbr\u00fcck Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glycotope and Max Delbr\u00fcck Center Enter into Research Collaboration to Explore Combination of GlycoTargets and CAR Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Glycotope","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Glycotope","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glycotope and Evotec Enter Licensing Agreement to Combine Glycotope Antibodies and Evotec\u2019s Immune Cell Engager Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Glycotope

    Menu

    Glycotope

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Glycotope

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Glycotope and Evotec Enter Licensing Agreement to Combine Glycotope Antibodies and Evotec’s Immune Cell Engager Platform

              Details:

              The agreement aims to combine Glycotope’s antibodies with Evotec’s immune cell engager platform for the development of next generation immune cell engaging bispecifics by Evotec.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Evotec

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement December 11, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Glycotope

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Development

              Details:

              The agreement aims to develop an antibody drug conjugate by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational antibodies. LCB has worldwide exclusive rights to develop and commercialize the selected antibody as an ADC.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: LegoChem Biosciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement October 16, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Glycotope

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Glycotope and Max Delbrück Center Enter into Research Collaboration to Explore Combination of GlycoTargets and CAR Technology

              Details:

              The collaboration aims to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (GlycoTargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Max Delbrück Center

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration September 25, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Glycotope

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Therabest and Glycotope to Assess Therabest’s iPSC-derived NK Cell Product TB-100 in Combination with Glycotope’s GT-00AxIL15 Immuno-cytokine For Development In Triple ...

              Details:

              The combination of Therabest’s iPSC derived NK cell therapy TB-100 and Glycotope’s tumor-targeted immuno-cytokine GT-00AxIL15 challenges the current NK cell therapy paradigm by converging a two-component platform improves the activity of TB-100.

              Lead Product(s): TB-100,GT-00AxIL15

              Therapeutic Area: Oncology Product Name: TB-100

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Recipient: Therabest

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Glycotope

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate

              Details:

              Glycotope’s antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GT-00X). Targeting these specific antigens enables broad indication range, long-term treatment potential and reduced on-target/off tumor toxicity.

              Lead Product(s): Antibody Drug Conjugate

              Therapeutic Area: Oncology Product Name: GT-00X

              Highest Development Status: Discovery Product Type: Large molecule

              Recipient: LegoChem Biosciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 12, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Glycotope

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Byondis , Glycotope Enter Platform Access Agreement Discovery and Development

              Details:

              Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs). Specific financial terms have not been disclosed.

              Lead Product(s): Antibody-drug Conjugate

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: Byondis

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 27, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY